Nothing Special   »   [go: up one dir, main page]

CY1122278T1 - Αντι il-36r αντισωματα - Google Patents

Αντι il-36r αντισωματα

Info

Publication number
CY1122278T1
CY1122278T1 CY20191101185T CY191101185T CY1122278T1 CY 1122278 T1 CY1122278 T1 CY 1122278T1 CY 20191101185 T CY20191101185 T CY 20191101185T CY 191101185 T CY191101185 T CY 191101185T CY 1122278 T1 CY1122278 T1 CY 1122278T1
Authority
CY
Cyprus
Prior art keywords
antibodies
therapeutic
compositions
relates
present
Prior art date
Application number
CY20191101185T
Other languages
English (en)
Inventor
Su-Ellen BROWN
Keith Canada
Lukasz CHLEWICKI
Michael Howell
Detlev Mennerich
Joseph Robert WOSKA JR.
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47215803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122278(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of CY1122278T1 publication Critical patent/CY1122278T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά αντι-IL-36R ενώσεις πρόσδεσης, ιδιαιτέρως νέα αντι-IL-36R αντισώματα και θεραπευτικές και διαγνωστικές μεθόδους και συνθέσεις για χρήση αυτών.
CY20191101185T 2011-11-16 2019-11-12 Αντι il-36r αντισωματα CY1122278T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161560554P 2011-11-16 2011-11-16
US201261644111P 2012-05-08 2012-05-08
US201261713713P 2012-10-15 2012-10-15
PCT/US2012/064933 WO2013074569A1 (en) 2011-11-16 2012-11-14 Anti il-36r antibodies

Publications (1)

Publication Number Publication Date
CY1122278T1 true CY1122278T1 (el) 2020-11-25

Family

ID=47215803

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191101185T CY1122278T1 (el) 2011-11-16 2019-11-12 Αντι il-36r αντισωματα
CY2023014C CY2023014I2 (el) 2011-11-16 2023-05-23 Αντι il-36r αντισωματα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2023014C CY2023014I2 (el) 2011-11-16 2023-05-23 Αντι il-36r αντισωματα

Country Status (39)

Country Link
US (3) US9023995B2 (el)
EP (2) EP2780373B1 (el)
JP (3) JP6289375B2 (el)
KR (3) KR20200110476A (el)
CN (5) CN118515766A (el)
AP (1) AP2014007571A0 (el)
AR (1) AR089178A1 (el)
AU (1) AU2012339734B2 (el)
BR (1) BR112014011594B1 (el)
CA (1) CA2852994C (el)
CL (1) CL2014001123A1 (el)
CO (1) CO7020871A2 (el)
CY (2) CY1122278T1 (el)
DK (1) DK2780373T3 (el)
EA (1) EA031948B1 (el)
EC (1) ECSP14004976A (el)
ES (1) ES2755732T3 (el)
FI (1) FIC20230020I1 (el)
FR (1) FR23C1023I2 (el)
HR (1) HRP20191835T1 (el)
HU (2) HUE047437T2 (el)
IL (2) IL232100B (el)
LT (2) LT2780373T (el)
MX (1) MX347164B (el)
MY (1) MY195289A (el)
NL (1) NL301233I2 (el)
NO (1) NO2023024I1 (el)
PE (1) PE20142041A1 (el)
PH (1) PH12014501108A1 (el)
PL (1) PL2780373T3 (el)
PT (1) PT2780373T (el)
RS (1) RS59248B1 (el)
SG (1) SG11201402283PA (el)
SI (1) SI2780373T1 (el)
TW (1) TWI573804B (el)
UA (1) UA115540C2 (el)
UY (1) UY34456A (el)
WO (1) WO2013074569A1 (el)
ZA (1) ZA201402491B (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
SG11201402283PA (en) 2011-11-16 2014-06-27 Boehringer Ingelheim Int Anti il-36r antibodies
AU2013203459B2 (en) 2012-02-24 2016-11-03 Abbvie Stemcentrx Llc DLL3 modulators and methods of use
LT3116909T (lt) * 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
RU2582569C2 (ru) * 2014-07-24 2016-04-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека, днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека с с-концевым полигистидиновым тагом, плазмидный экспрессионный вектор (варианты), штамм бактерий escherichia coli bl21 star[de3] (рет-il36raf), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 и штамм бактерий escherichia coli bl21 star[de3] (pet-il36raf-his), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 с с-концевым полигистидиновым тагом
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
NZ736535A (en) * 2015-04-15 2024-08-30 Anaptysbio Inc Antibodies directed against interleukin 36 receptor (il-36r)
US10723793B2 (en) * 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
JP6654773B2 (ja) * 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
KR20190098741A (ko) 2016-11-01 2019-08-22 아납티스바이오, 아이엔씨. T 세포 면역글로불린 및 뮤신 단백질 3(tim-3)에 대한 항체
MX2019008208A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-tim-3.
US20180273627A1 (en) * 2017-03-27 2018-09-27 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
AU2019205786B2 (en) * 2018-01-08 2023-12-14 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
MX2020009544A (es) * 2018-03-14 2020-10-05 Boehringer Ingelheim Int Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada.
CA3090421A1 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
SG11202012360YA (en) 2018-07-16 2021-01-28 Regeneron Pharma Anti-il36r antibodies
IL278267B1 (en) * 2018-07-16 2024-10-01 Regeneron Pharma NON-HUMAN ANIMAL MODELS OF DITRA DISEASE AND USES THEREOF
JP2022532812A (ja) 2018-08-16 2022-07-20 カンタージア アクチエボラーグ 抗ｉｌ１ｒａｐ抗体組成物
AU2019349958A1 (en) * 2018-09-28 2021-05-06 Kyowa Kirin Co., Ltd. IL-36 antibodies and uses thereof
MX2021007589A (es) * 2018-12-21 2021-12-10 23Andme Inc Anticuerpos anti il-36 y procedimientos de uso de estos.
EP3902604A1 (en) * 2018-12-27 2021-11-03 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for treatment of palmoplantar pustulosis
MX2021010783A (es) 2019-03-08 2021-09-30 Boehringer Ingelheim Int Formulaciones de anticuerpo anti-il-36r.
JPWO2021112196A1 (el) * 2019-12-05 2021-06-10
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
EP4153233A1 (en) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of atopic dermatitis
JP2023534955A (ja) 2020-07-17 2023-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 好中球性皮膚症の処置のための抗ｉｌ－３６ｒ抗体
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
CA3186601A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
JP2023544027A (ja) 2020-09-30 2023-10-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 慢性炎症性疼痛の処置のための抗ｉｌ－３６ｒ抗体
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
WO2022127842A1 (zh) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
CN114907477A (zh) * 2021-02-08 2022-08-16 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
BR112023014103A2 (pt) 2021-03-04 2023-10-10 Boehringer Ingelheim Int Métodos para o tratamento de gpp
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
AU2022269799A1 (en) * 2021-05-03 2023-09-14 Boehringer Ingelheim International Gmbh Method for producing spesolimab
WO2022262828A1 (zh) * 2021-06-18 2022-12-22 正大天晴药业集团股份有限公司 抗il-36r抗体及其用途
WO2023285362A1 (en) 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
WO2023019232A1 (en) 2021-08-13 2023-02-16 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for the treatment of a fibrotic condition
JP2024537724A (ja) 2021-09-28 2024-10-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 目に見える皮膚発現を有する好中球性皮膚疾患の重症度を評価するためのシステム及び方法
AU2022377057A1 (en) 2021-10-28 2024-05-09 Abbvie Inc. Anti-amyloid beta antibodies and methods of using the same
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用
US20240301074A1 (en) 2023-03-09 2024-09-12 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for the treatment of hidradentitis suppurativa (hs)

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
PT1003861E (pt) 1997-08-01 2007-01-31 Schering Corp Proteínas de membrana de células de mamíferos;reagentes relacionados
WO2001077342A1 (en) * 2000-04-11 2001-10-18 Genentech, Inc. Multivalent antibodies and uses therefor
EP1627927A3 (en) * 2001-03-01 2006-06-07 Epigenomics AG Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
AU2003282667A1 (en) * 2002-10-03 2004-04-23 Large Scale Biology Corporation Multimeric protein engineering
SG2014010029A (en) * 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
MX341064B (es) 2006-09-08 2016-08-05 Amgen Inc * Variantes de la familia il-1.
MX2009011500A (es) 2007-04-23 2010-01-29 Schering Corp Anticuerpos anti-mdl-1.
CA2691618A1 (en) 2007-06-29 2009-01-08 Schering Corporation Mdl-1 uses
CN102197051A (zh) 2008-08-28 2011-09-21 惠氏有限责任公司 Il-22、il-17 和il-1家族细胞因子在自身免疫疾病中的用途
SG11201402283PA (en) 2011-11-16 2014-06-27 Boehringer Ingelheim Int Anti il-36r antibodies
NZ736535A (en) 2015-04-15 2024-08-30 Anaptysbio Inc Antibodies directed against interleukin 36 receptor (il-36r)

Also Published As

Publication number Publication date
HRP20191835T1 (hr) 2019-12-27
BR112014011594B1 (pt) 2021-11-09
NO2023024I1 (no) 2023-05-30
NL301233I1 (el) 2023-06-07
CN118496365A (zh) 2024-08-16
UA115540C2 (uk) 2017-11-27
WO2013074569A1 (en) 2013-05-23
PH12014501108B1 (en) 2014-08-04
ECSP14004976A (es) 2015-11-30
CL2014001123A1 (es) 2015-01-23
FR23C1023I2 (fr) 2024-03-29
JP6289375B2 (ja) 2018-03-07
JP2020156506A (ja) 2020-10-01
EA031948B1 (ru) 2019-03-29
EP3536710A1 (en) 2019-09-11
CN104080808B (zh) 2016-11-16
KR102038310B1 (ko) 2019-11-01
US9023995B2 (en) 2015-05-05
SI2780373T1 (sl) 2019-12-31
RS59248B1 (sr) 2019-10-31
CN112812183A (zh) 2021-05-18
PT2780373T (pt) 2019-11-27
JP6719490B2 (ja) 2020-07-08
CA2852994C (en) 2023-02-14
NZ623425A (en) 2015-12-24
AU2012339734A1 (en) 2014-04-24
MY195289A (en) 2023-01-12
TWI573804B (zh) 2017-03-11
EA201400579A1 (ru) 2014-10-30
CN107007833B (zh) 2020-12-11
KR20200110476A (ko) 2020-09-23
JP2018093885A (ja) 2018-06-21
US20130236471A1 (en) 2013-09-12
LT2780373T (lt) 2019-09-25
US20200231684A1 (en) 2020-07-23
DK2780373T3 (da) 2019-11-04
KR20190122877A (ko) 2019-10-30
JP2015500633A (ja) 2015-01-08
KR102159109B1 (ko) 2020-09-23
AU2012339734B2 (en) 2017-02-16
ZA201402491B (en) 2021-09-29
LTPA2023518I1 (el) 2023-06-12
UY34456A (es) 2013-05-31
PH12014501108A1 (en) 2014-08-04
PE20142041A1 (es) 2014-12-18
CN104080808A (zh) 2014-10-01
KR20140101738A (ko) 2014-08-20
NL301233I2 (nl) 2023-09-13
MX347164B (es) 2017-04-18
CO7020871A2 (es) 2014-08-11
EP2780373B1 (en) 2019-08-21
IL272035A (en) 2020-02-27
FR23C1023I1 (fr) 2023-07-21
HUS2300021I1 (hu) 2023-07-28
US20170298135A9 (en) 2017-10-19
TW201333037A (zh) 2013-08-16
EP2780373A1 (en) 2014-09-24
CN118515766A (zh) 2024-08-20
IL232100A0 (en) 2014-05-28
CY2023014I1 (el) 2023-11-15
CN112812183B (zh) 2024-06-11
HUE047437T2 (hu) 2020-04-28
FIC20230020I1 (fi) 2023-06-01
CY2023014I2 (el) 2023-11-15
CA2852994A1 (en) 2013-05-23
US20150203584A1 (en) 2015-07-23
PL2780373T3 (pl) 2020-03-31
US10550189B2 (en) 2020-02-04
BR112014011594A2 (pt) 2017-07-04
AP2014007571A0 (en) 2014-04-30
SG11201402283PA (en) 2014-06-27
ES2755732T3 (es) 2020-04-23
MX2014005759A (es) 2014-09-08
IL232100B (en) 2020-04-30
CN107007833A (zh) 2017-08-04
AR089178A1 (es) 2014-08-06

Similar Documents

Publication Publication Date Title
CY1122278T1 (el) Αντι il-36r αντισωματα
CY1123145T1 (el) Anti-cd40 αντισωματα
CY1118014T1 (el) Aνti-il-23 αντισωματα
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
PH12014502406B1 (en) Anti-il-23p19 antibodies
CY1122978T1 (el) Αντισωματα εναντι-vla-4
UA115402C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
MX2014014678A (es) Molecula de union al antigeno especifico para el tejido objetivo.
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
EA201290642A1 (ru) Соединения и способы
CY1119195T1 (el) Νεες συνθεσεις για θεραπεια αμυοτροφικης πλευρικης σκληρυνσης
AR124605A2 (es) Anticuerpos anti-il-36r
AR123070A2 (es) Anticuerpos anti-il-23
TN2014000207A1 (en) Anti il-36r antibodies
CY1120307T1 (el) Καινοφανεις ενωσεις επιλεκτικων ανταγωνιστων του υποδοχεα νκ-3, φαρμακευτικες συνθεσεις και μεθοδοι χρησης σε διαμεσολαβουμενες απο υποδοχεις νκ-3 διαταραχες
TN2013000186A1 (en) Anti-il-23 antibodies
NZ626296A (en) Compositions and methods for antibodies targeting factor p